New combo attack on tough lymphoma: two immune therapies join forces
NCT ID NCT06213311
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This phase 2 trial is testing a combination of two immune-based therapies—axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)—in 40 people with large B cell lymphoma that has relapsed or not responded to first treatment. The goal is to see if the combination can control the disease better than standard options. Participants will receive both drugs by IV, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with large B cell lymphoma that has come back or not responded to initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The combination may cause serious side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- Engineered immune cells take aim at tough childhood leukemia